Payment overview · 2025
General Payments
$182.99
10 reported records · 5 companies
Healthcare provider profile · identity verified
Stephen Patrick Thies, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BONNER SPRINGS, KS · NPI 1669554176
Verified facts
What the public records show
CMS Open Payments records show Stephen Patrick Thies, M.D. received $182.99 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 47.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $87.23 | 47.7% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.03 | 27.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.88 | 8.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.46 | 7.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.39 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $182.99 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $53.51 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.51 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.03 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
57 | 56 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 338 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 219 | 31 |
| Lisinopril | Lisinopril | 216 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 206 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 56 |
| Omeprazole | Omeprazole | 180 | 48 |
| Losartan Potassium | Losartan Potassium | 167 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 52 |
| Gabapentin | Gabapentin | 150 | 32 |
| Simvastatin | Simvastatin | 142 | 42 |
| Tramadol Hcl | Tramadol Hcl | 137 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 122 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 30 |
| Alprazolam | Alprazolam | 111 | 17 |
| Trazodone Hcl | Trazodone Hcl | 107 | 25 |
| Metformin Hcl Er | Metformin Hcl | 95 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 16 |
| Jardiance | Empagliflozin | 80 | 13 |
| Potassium Chloride | Potassium Chloride | 79 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 78 | 59 |
| Meloxicam | Meloxicam | 77 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 22 |
| Ozempic | Semaglutide | 69 | suppressed |
| Metformin Hcl | Metformin Hcl | 67 | 18 |
| Mounjaro | Tirzepatide | 65 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 18 |
| Prednisone | Prednisone | 63 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 19 |
| Furosemide | Furosemide | 59 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 57 | 56 |
| Lovastatin | Lovastatin | 57 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 40 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 14 |
| Carvedilol | Carvedilol | 53 | 17 |
| Diazepam | Diazepam | 53 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 14 |
| Eliquis | Apixaban | 51 | suppressed |
| Baclofen | Baclofen | 49 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 17 |
| Sertraline Hcl | Sertraline Hcl | 49 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 46 | 14 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 11 |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 13 |
| Bupropion Xl | Bupropion Hcl | 39 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 20 |
| Azelastine Hcl | Azelastine Hcl | 34 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 12 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 30 | 23 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 30 | 30 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Verapamil Sr | Verapamil Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Qnasl | Beclomethasone Dipropionate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $182.99 · 10 records | PFIZER INC. | Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, NURTEC ODT, QULIPTA, UBRELVY, VYNDAMAX, VYNDAQEL, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error